A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

Last updated: November 7, 2011
Sponsor: Novartis
Overall Status: Completed

Phase

3

Condition

Circulation Disorders

Williams Syndrome

Stress

Treatment

N/A

Clinical Study ID

NCT00294710
CSPP100A2323E
  • Ages 18-80
  • All Genders

Study Summary

This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with essential hypertension

Exclusion

Exclusion Criteria:

  • Severe hypertension

  • History or evidence of a secondary form of hypertension

  • History of myocardial infarction.

  • Other protocol-defined inclusion exclusion criteria also apply.

Study Design

Total Participants: 976
Study Start date:
March 01, 2005
Estimated Completion Date:
July 31, 2006

Connect with a study center

  • Investigative Centers,
    Germany

    Site Not Available

  • Novartis

    East Hanover, New Jersey 07936
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.